Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)

• Company Description    Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif. Number of Employees: 370

• Price / Volume Information    Yesterday's Closing Price: $62.26 Daily Weekly Monthly 20 Day Moving Average: 765,222 shares Shares Outstanding: 43.02 (millions) Market Capitalization: $2,678.67 (millions) Beta: 0.52 52 Week High: $85.25 52 Week Low: $38.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.12% -2.87% 12 Week -17.94% -24.14% Year To Date -23.96% -28.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15440 LAGUNA CANYON ROAD SUITE 160 - IRVINE,CA 92618 USA ph: 949-418-1801 fax: - ir@tarsusrx.com http://www.tarsusrx.com

• General Corporate Information    Officers Bobak Azamian - President; Chief Executive Officer and Chairman Jeffrey Farrow - Chief Financial Officer and Chief Strategy Officer Bhaskar Chaudhuri - Director Andrew Goldberg - Director Katherine Goodrich - Director Peer Information Tarsus Pharmaceuticals, Inc. (CORR.) Tarsus Pharmaceuticals, Inc. (RSPI) Tarsus Pharmaceuticals, Inc. (CGXP) Tarsus Pharmaceuticals, Inc. (BGEN) Tarsus Pharmaceuticals, Inc. (GTBP) Tarsus Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87650L103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 43.02 Most Recent Split Date: (:1) Beta: 0.52 Market Capitalization: $2,678.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.68 Price/Cash Flow: - Price / Sales: 5.01 EPS Growth vs. Year Ago Period: 75.00% vs. Previous Quarter: 20.00% Sales Growth vs. Year Ago Period: 106.87% vs. Previous Quarter: 6.85% ROE 03/31/26 - -14.19 12/31/25 - -19.63 09/30/25 - -26.29 ROA 03/31/26 - -8.89 12/31/25 - -12.70 09/30/25 - -17.02 Current Ratio 03/31/26 - 3.74 12/31/25 - 3.85 09/30/25 - 4.29 Quick Ratio 03/31/26 - 3.71 12/31/25 - 3.82 09/30/25 - 4.25 Operating Margin 03/31/26 - -9.02 12/31/25 - -14.72 09/30/25 - -22.17 Net Margin 03/31/26 - -9.02 12/31/25 - -14.72 09/30/25 - -22.17 Pre-Tax Margin 03/31/26 - -7.33 12/31/25 - -14.26 09/30/25 - -22.17 Book Value 03/31/26 - 8.11 12/31/25 - 8.09 09/30/25 - 7.89 Inventory Turnover 03/31/26 - 8.38 12/31/25 - 8.30 09/30/25 - 7.57 Debt-to-Equity 03/31/26 - 0.21 12/31/25 - 0.21 09/30/25 - 0.22 Debt-to-Capital 03/31/26 - 17.22 12/31/25 - 17.42 09/30/25 - 17.74

Powered by Zacks Investment Research ©